Meta-analysis of efficacies of dasatinib and imatinib for patients with chronic myeloid leukemia-chronic phase / 白血病·淋巴瘤
Journal of Leukemia & Lymphoma
; (12): 228-233, 2016.
Article
en Zh
| WPRIM
| ID: wpr-494560
Biblioteca responsable:
WPRO
ABSTRACT
Objective To compare the efficiencies of imatinib and dasatinib in patients with chronic myeloid leukemia-chronic phase (CML-CP).Methods The databases were retrieved,including Cochrane Library,OVID,Embase,PubMed,China National Knowledge Infrastructure (CNKI),WanFang database and VIP database,besides,references of articles were further to search.The quality of randomized controlled trials (RCTs) was assessed by the Cochrane collaboration' s risk tool.Meta-analysis was performed by RevMan 5.1 software.Results A total of 5 articles involved 2 031 patients with CML-CP were included.Meta-analysis showed that the rate of complete cytogenetic response (CCyR) at the 12th month in dasatinib group was higher than that in imatinib group [83.6 ％ (478/572) vs 70.6 ％ (406/575),OR =2.11,95 ％ CI 1.59-2.80,P＜ 0.05],and the rate of major molecular response (MMR) at the 12th month in dasatinib group was higher than that in imatinib group [49.3 ％ (296/600) vs 30.6 ％ (185/605),OR =2.22,95 ％ CI 1.75-2.82,P ＜ 0.05].Conclusion Dasatinib can improve CCyR and MMR rate at the 12th month in CML-CP patients.
Texto completo:
1
Base de datos:
WPRIM
Tipo de estudio:
Clinical_trials
/
Systematic_reviews
Idioma:
Zh
Revista:
Journal of Leukemia & Lymphoma
Año:
2016
Tipo del documento:
Article